Drug name
Last update: Sep 2026Zinlirvimab (ZAB)
Developer(s)
Drug information
Not provided
Zinlirvimab; GS-2872; 10-1074-LS; 10-1074-LS-J
Not applicable (investigational; no brand name assigned)
Biotherapeutic
bNAb targeting the V3 glycan supersite (base of the V3 loop) of gp120 on HIV-1 envelope
Zinlirvimab (GS-2872) is the LS variant of the broadly neutralising antibody 10-1074, discovered at The Rockefeller University and licensed to Gilead Sciences in January 2020. It is a fully human IgG1 lambda that binds the base of the V3 loop of gp120 and neutralises around 61% of viral strains; it differs from 10-1074 only by two Fc substitutions that increase FcRn affinity. After a single 2,550 mg IV infusion in people with HIV the mean half-life was 89.1 days; in viraemic participants it was 47.6 days. It is developed with teropavimab and lenacapavir as a twice-yearly regimen (phase 3 Daybreak 1 & 2). In the RIO trial most rebound viruses in the bNAb arm were significantly resistant to 10-1074-LS.
Not approved in any jurisdiction as of September 2026.
Unknown
Therapeutic area(s)
- HIV
- Treatment
Administration route
Subcutaneous, Intramuscular
Associated long-acting platforms
Monoclonal antibodies and antibody drug conjugates
Use of drug
- Administered by a nurse
- Administered by a specialty health worker
- Every 6 months
Dosage
Investigational: 2,550 mg IV infusion.
2,550 mg IV (regimen dose)
No approved regimen. Given as 2,550 mg IV every 6 months with teropavimab 2,550 mg IV and lenacapavir SC in clinical trial.
Susceptibility screening to both antibodies required in the Gilead programme.
Not provided
Associated compounds, formulations and regimens
Associated technologies
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
Not reported for this product. Generic mAb scale-up considerations apply: formulation stability at high concentration, pharmacokinetic suitability, and maintenance of critical quality attributes
Not reported for this product.
Recombinant human IgG1 lambda produced in mammalian cell culture by Gilead. Process details not published.
Not reported for this product. Standard mAb characterisation applies: ion-exchange chromatography and capillary isoelectric focusing (charge variants), size-exclusion chromatography (aggregates), DSC (thermal stability), subvisible particle counting, ELISA for serum concentrations, TZM.bl neutralisation assays for susceptibility.
Excipients & delivery device(s)
Not provided
Not provided
Not provided
No delivery device
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL